|Healthcare Review: Peregrine Pharmaceuticals, Repligen Corporation, InterMune Are Top Gainers|
|By Staff and Wire Reports|
|Monday, 10 September 2012 14:42|
The Fed is more likely to take less dramatic steps in the short term, such as extending guidance for keeping interest rates at exceptionally low levels into 2015. Several healthcare stocks are making notable news at mid day on Monday.
Peregrine Pharmaceuticals (NASDAQ:PPHM) shares jumped 9.72% to $4.95. The company announced that interim results from its Phase IIb trial in patients with refractory non-small cell lung cancer showed a statistically significant improvement in overall survival and a doubling of median overall survival in the bavituximab-containing arms, compared to the control arm.
Additionally, Roth Capital restated their buy rating on shares of PPHM and the firm currently has a $5.00 price target on the stock.
Repligen Corporation (NASDAQ:RGEN) stock gained 12.29% to $6.03 on no official news. The 52 week trading range for the company is $2.90 - $7.29. The shares of the company soared 81% in the last one year. The company is a supplier of critical products used to manufacture biologic drugs. The Company manufactures Protein A for life science companies under long term supply agreements and also sell products directly to end users for use in their manufacturing processes.
BioMimetic Therapeutics, Inc.(NASDAQ:BMTI) stock climbed 5.03% to $4.16 in the early trading hour. The 52 week trading range for the company is $1.87 - $4.30. The shares of BMTI gained 27% in the last one year. The company is a biotechnology company. The Company is engaged in developing and commercializing products to the healing of musculoskeletal injuries and diseases, including therapies for orthopedic, sports medicine and spine applications.
InterMune, Inc.(NASDAQ:ITMN) shares climbed 8.69% to $8.63 in the early hour. Canaccord Genuity reiterates a 'Hold' on InterMune and set the price target of $11.00. Additionally, analysts predict that ITMN will post $-2.73 earnings per share for the current fiscal year. The 52 week trading range for the company is $7.21 - $27.93.
Curis, Inc.(NASDAQ:CRIS) shares increased 4.75% to $4.41. The company announced that the Company will present at the Rodman & Renshaw Annual Global Investment Conference - Tuesday, September 11, at 2:00 p.m. EDT in New York City.
Additionally, Piper Jaffray restated their overweight rating on shares of Curis in a research note issued to investors today. The firm currently has a $7.00 target price on the stock.